Description
The ProbeSeq Cardiac Troponin I (cTnI) Nanobody is a recombinant single-domain antibody (VHH) engineered for high-affinity and selective binding to human cardiac troponin I, a regulatory protein released into circulation following myocardial injury. This nanobody supports research-use diagnostic assay development, cardiac biomarker detection, and advanced biosensor integration.
Cardiac troponin I is widely recognized as the gold-standard biomarker for detection of myocardial infarction and cardiac injury. Elevated circulating levels reflect cardiomyocyte damage and are central to acute coronary syndrome diagnosis and cardiac monitoring. Rapid and sensitive detection of cTnI is critical for cardiovascular research, emergency diagnostics, and development of rapid point-of-care testing technologies.
Derived from camelid heavy-chain antibody architecture, this nanobody consists of a single monomeric VHH domain (~15 kDa) providing strong antigen recognition, rapid binding kinetics, and high structural stability. Compared with conventional antibodies, nanobodies offer enhanced thermal stability, efficient surface immobilization, and reduced steric hindrance, enabling high-performance detection in electrochemical biosensors, microfluidic devices, and miniaturized diagnostic platforms.
Typical assay workflows use sample input volumes ranging from approximately 5–50 µL depending on platform configuration and detection method. The nanobody is compatible with serum, plasma, whole blood extracts, and buffered biological samples following appropriate assay optimization.
What’s Included
Recombinant anti-cTnI single-domain VHH nanobody
Sequence and expression documentation for research traceability
Reconstitution and handling guidelines
Custom affinity tags (His-tag, biotin, Fc fusion), labeling options, and bulk production available upon request.
Target Strategy
Engineered for high binding specificity to cardiac troponin I epitopes
Minimal cross-reactivity with related troponin subunits
Stable binding under physiological conditions
Compatible with biosensor surface functionalization and immunoassay workflows
Product Format
Lyophilized format
Delivered dry for enhanced stability
Reconstitute in PBS or preferred buffer
Solution format
Supplied in PBS-based storage buffer
Typical concentration range 0.5–1 mg/mL
Tagged variants available upon request.
Performance Orientation
Electrochemical biosensors
Cardiac immunoassay development
Microfluidic and lab-on-chip systems
Surface immobilization workflows
Optical and fluorescence detection platforms
Point-of-care cardiac diagnostic research devices
Quality Control
Sequence confirmation
Purity validation (SDS-PAGE / chromatography)
Binding verification testing
Concentration determination
Manufacturing quality review
Certificate of Analysis (CoA) available upon request.
Applications
Myocardial infarction biomarker detection research
Cardiovascular disease monitoring studies
Acute coronary syndrome research
Immunoassay and biosensor development
Microfluidic diagnostic platform integration
Point-of-care cardiac monitoring research
Storage
Store at –20 °C for long-term storage or 4 °C for short-term use.
Lyophilized nanobody stable for up to 12 months under recommended conditions. Avoid repeated freeze–thaw cycles.
